Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer

BACKGROUND: We studied the utility of the tumor suppressor Tristetraprolin (TTP, ZFP36) as a clinically relevant biomarker of aggressive disease in prostate cancer patients after radical prostatectomy (RP). METHODS: TTP RNA expression was measured in an RP cohort of patients treated at Moffitt Cance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Epidemiol Biomarkers Prev
Main Authors: Rounbehler, Robert J., Berglund, Anders E., Gerke, Travis, Takhar, Mandeep M., Awasthi, Shivanshu, Li, Weimin, Davicioni, Elai, Erho, Nicholas G., Ross, Ashley E., Schaeffer, Edward M., Klein, Eric A., Karnes, R. Jeffrey, Jenkins, Robert B., Cleveland, John L., Park, Jong Y., Yamoah, Kosj
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6214732/
https://ncbi.nlm.nih.gov/pubmed/30108099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-18-0369
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados